Dulera ([mometasone + formoterol]; Merck & Co) is an oral inhalation drug that contains a combination of mometasone (an inhaled corticosteroid) and formoterol (a long-acting beta 2 agonist). Mometasone is a glucocorticoid receptor agonist with potent anti-inflammatory activity. Formoterol fumarate is a beta-2 adrenergic receptor agonist and acts as a bronchodilator. Dulera is approved in the US where it is indicated for the treatment of asthma in adults and adolescents aged 12 years and above.
TABLE OF CONTENTS
4 Product Profiles
4 Dulera : Asthma
LIST OF FIGURES
10 Figure 1: Dulera for asthma – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Dulera in asthma
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Dulera in asthma
14 Figure 4: Dulera sales for asthma in the US, 2017–26
LIST OF TABLES 4 Table 1: Dulera drug profile
6 Table 2: Dulera pivotal trial data in asthma
9 Table 3: Dulera Phase IV trial in asthma
15 Table 4: Dulera sales for asthma in the US ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.